SCHEMBL1664335

SCHEMBL1664335

CC(C)c1nc2ccccc2c(=O)n1-c1ccc(I)cc1.COc1cc(-n2c(C(C)C)nc3cc(O)ccc3c2=O)ccc1C#N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.59
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
KCNH2 Q12809 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
PDE10A Q9Y233 2/20 0.39
KMT2A Q03164 6/20 0.39
ACHE P22303 1/20 0.39
MEN1 O00255 5/20 0.39
MAPT P10636 2/20 0.39
GLA P06280 1/20 0.39
PKM P14618 1/20 0.39
MCL1 Q07820 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1664011 0.81 TRPV1 (0.72) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL10446213 0.78 TRPV1 (0.72) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1663868 0.76 TRPV1 (0.63) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1066896 0.76 TRPV1 (1.00) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL29383546 0.76 TRPV1 (1.00) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL10446219 0.75 TRPV1 (0.71) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1663409 0.75 TRPV1 (0.69) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL23273575 0.74 TRPV1 (0.65) TRPV1ESR1ESR2KMT2AMAPT
SCHEMBL29656833 0.74 TRPV1 (0.65) TRPV1ESR1ESR2KMT2AMAPT
SCHEMBL1664223 0.73 TRPV1 (0.55) TRPV1ESR1ESR2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.